Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia
15 juin 2021 07h00 HE
|
Axsome Therapeutics, Inc.
Submission anticipated in 4Q 2022 NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the...